In 2023, Xie D et al. conducted preclinical research in which they developed a biscistronic CAR (123CL CAR) capable of targeting both CD123 and CLL1 to eliminate AML cells both in vitro and in vivo [83]. Here, CLEC12A is linked to acute myeloid leukemia.